SAN

92.15

+0.96%↑

SRT3

229.9

+1.68%↑

BIM

115.6

+0.7%↑

GXI

59.7

+0.93%↑

ICAD

21.5

+0.47%↑

SAN

92.15

+0.96%↑

SRT3

229.9

+1.68%↑

BIM

115.6

+0.7%↑

GXI

59.7

+0.93%↑

ICAD

21.5

+0.47%↑

SAN

92.15

+0.96%↑

SRT3

229.9

+1.68%↑

BIM

115.6

+0.7%↑

GXI

59.7

+0.93%↑

ICAD

21.5

+0.47%↑

SAN

92.15

+0.96%↑

SRT3

229.9

+1.68%↑

BIM

115.6

+0.7%↑

GXI

59.7

+0.93%↑

ICAD

21.5

+0.47%↑

SAN

92.15

+0.96%↑

SRT3

229.9

+1.68%↑

BIM

115.6

+0.7%↑

GXI

59.7

+0.93%↑

ICAD

21.5

+0.47%↑

Search

Orion Oyj (Class B)

Deschisă

54.95 -0.36

Rezumat

Modificarea prețului

24h

Curent

Minim

54.4

Maxim

55.7

Indicatori cheie

By Trading Economics

Venit

-12M

61M

Vânzări

-80M

355M

P/E

Medie Sector

22.682

54.379

EPS

0.44

Randament dividend

2.92

Marjă de profit

17.287

Angajați

3,943

EBITDA

136M

202M

Dividende

By Dow Jones

Randament dividend

Medie Sector

2.92%

2.55%

Statistici piață

By TradingEconomics

Capitalizare de piață

2.4B

7.9B

Deschiderea anterioară

55.31

Închiderea anterioară

54.95

Orion Oyj (Class B) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 mai 2025, 23:59 UTC

Top știri
Câștiguri

Naver 1Q Net Slumps on Higher Costs

8 mai 2025, 23:39 UTC

Câștiguri

OCBC 1Q Net Down on Lower Interest Income

8 mai 2025, 23:01 UTC

Câștiguri

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 mai 2025, 22:52 UTC

Câștiguri

REA Expects Annual Listings Growth Despite April Decline

8 mai 2025, 22:46 UTC

Câștiguri

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 mai 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

8 mai 2025, 23:45 UTC

Market Talk

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 mai 2025, 23:41 UTC

Market Talk

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 mai 2025, 23:30 UTC

Câștiguri

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 mai 2025, 23:29 UTC

Câștiguri

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 mai 2025, 23:22 UTC

Câștiguri

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 mai 2025, 23:22 UTC

Câștiguri

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 mai 2025, 23:21 UTC

Câștiguri

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 mai 2025, 23:21 UTC

Câștiguri

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 mai 2025, 23:17 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 mai 2025, 23:17 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 mai 2025, 23:17 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 mai 2025, 23:05 UTC

Market Talk

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 mai 2025, 23:05 UTC

Market Talk

Global Equities Roundup: Market Talk

8 mai 2025, 23:01 UTC

Top știri

With U.K. Deal, U.S. Signals That 10% Tariff on World Is New Baseline -- WSJ

8 mai 2025, 22:28 UTC

Câștiguri

REA Expects FY 2025 Listings Growth of 1-2%

8 mai 2025, 22:28 UTC

Câștiguri

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 mai 2025, 22:27 UTC

Câștiguri

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 mai 2025, 22:27 UTC

Câștiguri

REA Says April Residential Listings Fell by 11% on Year

8 mai 2025, 22:26 UTC

Câștiguri

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 mai 2025, 22:26 UTC

Câștiguri

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 mai 2025, 22:26 UTC

Câștiguri

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 mai 2025, 22:26 UTC

Câștiguri

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 mai 2025, 22:25 UTC

Câștiguri

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 mai 2025, 22:25 UTC

Câștiguri

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

Comparație

Modificare preț

Orion Oyj (Class B) Așteptări

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Orion Oyj (Class B)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.